Last 33.00 GBp
Change Today -0.25 / -0.75%
Volume 78.0K
SCLP On Other Exchanges
As of 11:35 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

scancell holdings plc (SCLP) Snapshot

33.25 GBp
Previous Close
33.25 GBp
Day High
33.25 GBp
Day Low
33.00 GBp
52 Week High
02/11/14 - 40.00 GBp
52 Week Low
08/6/14 - 28.00 GBp
Market Cap
Average Volume 10 Days
-0.01 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for SCANCELL HOLDINGS PLC (SCLP)

Related News

No related news articles were found.

scancell holdings plc (SCLP) Related Businessweek News

No Related Businessweek News Found

scancell holdings plc (SCLP) Details

Scancell Holdings PLC, a biopharmaceutical company, engages in the discovery and development of novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms in the United Kingdom. It is involved in the development of SCIB1, a plasmid DNA vaccine, which is in I/II clinical trials for the treatment of melanoma; and SCIB2 that stimulates immune responses to the lung cancer antigen NY-ESO-1. The company has collaborations with Cancer Research Technology Limited; Immatics Biotechnologies GmbH; NIH; ImmunoVaccine Technologies; Ichor Medical Systems; and Merck KGaA. Scancell Holdings PLC was incorporated in 2008 and is based in Nottingham, the United Kingdom.

7 Employees
Last Reported Date: 09/3/14

scancell holdings plc (SCLP) Top Compensated Officers

Joint Chief Executive Officer, Chief Scientif...
Total Annual Compensation: 76.7K GBP
Joint Chief Executive Officer and Director
Total Annual Compensation: 70.0K GBP
Compensation as of Fiscal Year 2014.

scancell holdings plc (SCLP) Key Developments

Scancell Holdings PLC Reports Unaudited Consolidated Earnings Results for the Six Months Ended October 31, 2014

Scancell Holdings PLC reported unaudited consolidated earnings results for the six months ended October 31, 2014. For the period, the company's operating loss was £1,560,813 compared to £1,306,556 a year ago. Loss before taxation was £1,489,915 compared to £1,302,574 a year ago. Loss attributable to equity holders of the parent company was £1,339,915 or £0.60 per basic and diluted share compared to £1,187,574 or £0.57 per basic and diluted share a year ago. Net cash used in operating activities was £1,335,080 compared to £1,170,006 a year ago. The major reason for the increased loss in the period is additional expenditure on development which has been partially offset by a reduction in administration expenses.

Scancell Holdings Plc Announces Change of Registered Office

Scancell Holdings Plc announced the change of the company's registered office to: Eversheds House, 70 Great Bridgewater Street, Manchester, M1 5ES, United Kingdom.

Scancell Holdings Provides Research and Development Update Highlights Progress in Both SCIB1 Clinical Trial and Moditope® Platform

Scancell Holdings PLC provided a research and development update following the company's AGM. Dr. Richard Goodfellow and Prof Lindy Durrant, Scancell's joint CEOs, will present an update on progress with the new Moditope platform as well as the ongoing SCIB1 Phase 1/2 clinical trial in malignant melanoma, the lead programme from the company's ImmunoBodyÒ platform. The company announced further encouraging data from the on-going Phase 1/2 clinical trial in patients with Stage III/IV melanoma treated with SCIB1. To date, 32 patients have been treated with SCIB1, including seven at the higher 8mg dose. Six patients are currently on long-term treatment and have received between 4 and 6 further doses of SCIB1 every 3-6 months. Although recruitment of patients with advanced disease remains challenging it is expected that enrolment for the study will be completed during 2Q15. A new clinical centre has been established at the Royal Surrey County Hospital in Guildford to accelerate recruitment. SCIB1 continues to be a safe and well tolerated treatment with no withdrawals from the study due to adverse events. Overall, only five of the 27 patients who have received at least three doses of 2-8mg SCIB1 since commencement of the study in 2010 have died. Median survival time in Part 1 patients who received at least three treatments with the 2mg/4mg doses of SCIB1 is now 34 months since study entry. This group of patients had 1-year, 2-year and 3-year survival rates of 100%, 67% and 50%, respectively. For the Part 1 8mg cohort of patients, who were recruited later, the median survival time is currently 13 months since study entry. The median survival time since initiating treatment with SCIB1 in Part 2 patients with resected disease (and receiving 4mg doses of SCIB1) is currently 25 months. Importantly, all 16 patients (two in Part 1 and 14 in Part 2) with fully-resected metastatic disease (nine Stage III and seven Stage IV) are still alive with a median survival time of 26 months since study entry (range 20-39 months) and only four have shown evidence of disease progression. The Stage III patients have a median survival time of 26 months since study entry and two (22%) have progressed. This compares extremely favourably with results from a peptide vaccine trial (Slingluff et al., 2011) where 52% of fully-resected Stage III patients had progressed and 33% had died two years after the start of treatment. The Stage IV patients treated with SCIB1 have a median survival time of 24 months since study entry and two of these patients (22%) have also progressed. In the Slingluff study, 50% of the fully-resected Stage IV patients had progressed and 19% had died after two years of treatment. These results in patients with resected disease suggest that SCIB1 may have an important role to play as first line treatment in adjuvant melanoma. These are patients who no longer have measurable disease (following surgery) and are often generally quite well. However, they are at a high risk of recurrence and currently have very few, if any, effective treatment options. This represents a significant and as yet untapped market opportunity, including some 360,000 patients in the US alone, of whom around 45% have the MHC antigen HLA-A2 and are therefore suitable for SCIB1 treatment. Animal data supporting the synergistic effect of combining SCIB1 with PD-1 blockade was announced in August. Any patients that progress following SCIB1 monotherapy, or indeed any patient with more advanced disease, may therefore benefit from the combination of SCIB1 with a checkpoint inhibitor. Scancell's Immunobody® immunotherapy platform enhances the uptake and presentation of cancer antigens to harness the high avidity T cell responses that destroy tumours. The platform has been validated both in animals and in the clinic with SCIB1 but many opportunities also exist for the development of a pipeline of ImmunoBody® vaccines, both for cancer and chronic infectious diseases. A second ImmunoBody® vaccine targeting the lung cancer antigen NY-ESO-1 (SCIB2) has been developed to the point at which the product is fully defined and ready for further preclinical development as a potential immunotherapy for any tumour that expresses the NY-ESO-1 antigen such as lung, oesophageal, gastric, ovarian and bladder cancers. During the past 12 months research on other ImmunoBody® vaccines for prostate, liver and colorectal cancer have also been further advanced.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLP:LN 33.00 GBp -0.25

SCLP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCLP.
View Industry Companies

Industry Analysis


Industry Average

Valuation SCLP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCANCELL HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at